Depression and diabetes: From epidemiology to neurobiology;Depresión y diabetes: De la epidemiología a la neurobiología

Revista de Neurologia

Volumn 51, Issue 6, 2010, Pages 347-359

  Castillo Quan, Jorge I ^a   Barrera Buenfil, Divia J ^a   Pérez Osorio, Julia M ^a   Álvarez Cervera, Fernando J ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

Author keywords

BDNF; Cortisol; Depression; Diabetes; GSK 3; Insulin; Psychological distress; Serotonin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3; HYDROCORTISONE; MONOAMINE; NORADRENALIN; SEROTONIN;

BLOOD GLUCOSE MONITORING; CLINICAL STUDY; DEPRESSION; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; EMOTIONALITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MORBIDITY; MORTALITY; NEUROBIOLOGY; NEUROCHEMISTRY; NONHUMAN; PSYCHOSOCIAL ADJUSTMENT TO ILLNESS SCALE; REVIEW;

EID: 78649861241     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5106.2009398     Document Type: Review

References (87)

1. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a life-span perspective. Lancet Neurol 2008; 7: 184-90.
2. Castillo-Quan JI, Barrera-Buenfil DJ, Pérez-Osorio JM. The role of insulin and cortisol on memory and Alzheimer's disease pathology: implications for diabetes mellitus. Cambridge Med 2008; 22: 31-5.
3. Castillo-Quan JI. Rosiglitazone effects to ameliorate Alzheimer's disease pathogenic features: focusing in the insulin signaling and neurotrophic factors. J Neuropsychiatry Clin Neurosci 2009; 21: 347-8.
4. Den Heijer T, Vermeer SE, Van Dijk EJ, Prins ND, Koudstaal PJ, Hofman A, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46: 1604-10.
5. Fisher L, Skaff MM, Mullan JT, Arean P, Mohr D, Masharani U, et al. Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. Diabetes Care 2007; 30: 542-8.
6. González JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga SJ, et al. Depression and diabetes treatment non-adherence: a meta-analysis. Diabetes Care 2008; 31: 2398-403.
7. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001; 63: 619-30.
8. Castillo-Quan JI. La terapia farmacológica subaguda con litio mejora la conducta depresiva, memoria espacial y glucemia en ratas con diabetes inducida: efecto potencial sobre la glucógeno sintasa cinasa-3 [tesis]. Mérida: Facultad de Medicina. Universidad Autónoma de Yucatán; 2009.
9. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder. Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289: 3095-105.
10. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
11. DSM-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. Barcelona: Masson; 2003.
12. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.
13. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291: 2581-90.
14. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 21-7.
15. Bello M, Puentes-Rosas E, Medina-Mora ME, Lozano R. Prevalencia y diagnóstico de depresión en población adulta en México. Salud Publica Mex 2005; 47 (Supl 1): S4-11.
16. World Health Organization. The World Health Report 2004: changing history. Annex Table 3: burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for 2002. Geneva: WHO; 2004.
17. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 2005; 62: 617-27.
18. WHO South-East Asia Regional Office. Conquering depression. WHO, 2001. URL: URL: www.searo.who.int/LinkFiles/conquering-depression-ment-120.pdf. [12.05.2009].
19. Simon GE, Katon WJ, Lin EH, Rutter C, Manning WG, Von Korff M, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007; 64: 65-72.
20. Zimmet P, Alberti KG, Shaw J. Global epidemic and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
21. Castillo-Quan JI, Pérez-Osorio JM. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications: response to Chiodini et al. Diabetes Care 2007; 30: e49.
22. Castillo-Quan JI. Insulin resistance, hypercortisolism, polycystic ovarian syndrome, and depression -nonrandom associations? Fertil Steril 2008; 89: 1029-30.
23. Kovacs M, Goldsston D, Obrosky DS, Bonar L. Psychiatric disorders in youths with IDDM: rates and risk factors. Diabetes Care 1997; 20: 36-44.
24. Eaton WW. Epidemiologic evidence on the comorbidity of depression and diabetes. J Psychosom Res 2002; 53: 903-6.
25. Martínez-Carpio PA, Barba J, Bedoya-Del Campillo A. Relación entre niveles de colesterol y trastornos neuropsiquiá tricos. Rev Neurol 2009; 48: 261-4.
26. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-7.
27. González, JS, Safren SA, Delahanty LM, Cagliero E, Wexler DJ, Meigst JB, et al. Symptoms of depression prospectively predict poorer self-care in patients with type 2 diabetes. Diabet Med 2008; 25: 1102-7.
28. Simon GE, Katon WJ, Lin EH, Ludman E, VonKorff M, Ciechanowski P, et al. Diabetes complications and depression as predictors of health service costs. Gen Hosp Psychiatry 2005; 27: 344-51.
29. Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000; 23: 618-23.
30. Gülseren L, Gülseren S, Hekimsoy Z, Mete L. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005; 36: 159-65.
31. Lustman PJ, Williams MM, Sayuk GS, Nix BD, Clouse RE. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007; 30: 459-66.
32. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006; 67: 1856-61.
33. Katon W, Fan MY, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. J Gen Intern Med 2008; 23: 1571-5.
34. Caruncho HJ, Rivera-Baltanás T. Biomarcadores de la depresión. Rev Neurol 2010; 50: 470-6.
35. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
36. Mello AA, Mello MF, Carpenter LL, Price LH. Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. Rev Bras Psiquiatr 2003; 25: 231-8.
37. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr 2004; 26: 189-201.
38. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31: 464-8.
39. Calfa G, Kademian S, Ceschin D, Vega G, Rabinovich GA, Volosin M. Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment. Psychoneuroendocrinology 2003; 28: 687-701.
40. Prieto-Moreno GA, Rosenstein Y. The links between the neuroendocrine and the immune systems: views of an immunologist. In Joseph-Bravo P, ed. Molecular endocrinology. Kerala: Research Signpost; 2006. p. 171-92.
41. Bastarrachea RA, López-Alvarenga JC, Bolado-García VE, Téllez-Mendoza J, Laviada-Molina H, Comuzzie AG. Macrophages, inflammation, adipose tissue, obesity and insulin resistance. Gac Med Mex 2007; 143: 505-12.
42. Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 2007; 12: 1079-88.
43. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008; 63: 642-9.
44. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997; 8: 523-32.
45. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23: 238-45.
46. Hilakivi-Clarke LA, Wozniak KM, Durcan MJ, Linnoila M. Behavior of streptozotocin-diabetic mice in test of exploration, locomotion, anxiety, depression and aggression. Physiol Behav 1990; 48: 429-33.
47. Gómez R, Huber J, Tombini G, Barros HM. Acute effect of different antidepressants on glycemia in diabetic and non-diabetics rats. Braz J Med Biol Res 2001; 34: 57-64.
48. Rowland NE, Bellush LL. Diabetes mellitus: stress, neuro chemistry and behavior. Neurosci Biobehav Rev 1989; 13: 199-206.
49. Gómez R, Vargas CR, Wajner M, Barros HM. Lower in vivo brain extracellular GABA concentration in diabetic rats during forced swimming. Brain Res 2003; 968: 281-4.
50. Bellush LL, Reid SG, North D. The functional significance of biochemical alterations in streptozotocin-induced diabetes. Physiol Behav 1991; 50: 973-81.
51. Manjarrez-Gutiérrez G, Rocío Herrera-Márquez JR, Bueno-Santoyo S, González-Ramírez M, Hernández J. Changes in brain serotonin biosynthesis in rats with diabetes mellitus induced by streptozotocin: effect of insulin treatment. Rev Invest Clin 2000; 52: 509-16.
52. Sandrini M, Vitale G, Vergoni AV, Ottani A, Bertolini A. Streptozotocin-induced diabetes provokes changes in serotonin concentration and on 5-HT1a and 5-HT2 receptors in the rat brain. Life Sci 1997; 60: 1393-7.
53. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 1996; 736: 54-60.
54. Chiodini I, Torlontano M, Scillitani A, Arosio M, Bacci S, Di Lembo S, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol 2005; 153: 837-44.
55. Chiodini I, Adda G, Scillitani A, Coletti F, Morelli V, Di Lembo S, et al. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 2007; 30: 83-8.
56. Chan O, Chan S, Inouye K, Vranic M, Matthews SG. Molecular regulation of the hypothalamo-pituitary-adrenal axis in streptozotocin-induced diabetes: effects of insulin treatment. Endocrinology 2001; 142: 4872-9.
57. Fruehwald-Schultes B, Kern W, Bong W, Wellhoener P, Kerner W, Born J, et al. Supraphysiological hyperinsulinemia acutely increases hypothalamic- pituitary-adrenal secretory activity in humans. J Clin Endocrinol Metab 1999; 84: 3041-6.
58. Castillo-Quan JI, Herrera-González A, Pérez-Osorio JM. Insulin-cortisol interaction in depression and other neurological diseases: an alternative hypothesis. Psychoneuro endocrinology 2007; 32: 854-5.
59. Chan O, Inouye K, Akirav EM, Park E, Riddell MC, Matthews SG, et al. Hyperglycemia does not increase basal hypothalamo-pituitary-adrenal activity in diabetes but it does impair the HPA response to insulin-induced hypoglycemia. Am J Physiol Regul Integr Comp Physiol 2005; 289: 235-46.
60. Forget H, Lacroix A, Somma M, Cohen H. Cognitive decline in patients with Cushing's syndrome. J Int Neuropsychol Soc 2000; 6: 20-9.
61. Fujinami A, Ohta K, Obayashi H, Fukui M, Hasegawa G, Nakamura N, et al. Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance. Clin Biochem 2008; 41: 812-7.
62. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50: 431-8.
63. Gómez-Pinilla F. Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 2008; 9: 568-78.
64. Yamanaka M, Tsuchida A, Nakagawa T, Nonomura T, Ono-Kishino M, Sugaru E, et al. Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice. Diabetes Obes Metab 2007; 9: 59-64.
65. Yamanaka M, Itakura Y, Inoue T, Tsuchida A, Nakagawa T, Noguchi H, et al. Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice. Metabolism 2006; 55: 1286-92.
66. Cohen P. The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol 2006; 7: 867-73.
67. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-76.
68. Johnson-Farley NN, Travkina T, Cowen DS. Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J Pharmacol Exp Ther 2006; 316: 1062-9.
69. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 2001; 177: 125-34.
70. O'Brien WT, Harper AD, Jové F, Woodgett JR, Maretto S, Piccolo S, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24: 6791-8.
71. Silva R, Mesquita AR, Bessa J, Sousa JC, Sotiropoulos I, Leão P, et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008; 152: 656-69.
72. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 2007; 61: 216-22.
73. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuro psychopharmacology 2004; 29: 32-8.
74. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 2006; 49: 837-45.
75. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008; 31: 2383-90.
76. Patten SB, Williams JV, Lavorato DH, Brown L, McLaren L, Eliasziw M. Major depression, antidepressant medication and the risk of obesity. Psychother Psychosom 2009; 78: 182-6.
77. Herva A, Laitinen J, Miettunen J, Veijola J, Karvonen JT, Läksy K, et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes (Lond) 2006; 30: 520-7.
78. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 59: 241-50.
79. Weber-Hamann B, Gilles M, Schilling C, Onken V, Frankhauser P, Kopf D, et al. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine. J Clin Psychopharmacol 2008; 28: 581-4.
80. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-8.
81. Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N. Psychiatric medication-induced obesity: a review. Obes Rev 2004; 5: 115-21.
82. Kloiber S, Ising M, Reppermund S, Horstmann S, Dose T, Majer M, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry 2007; 62: 321-6.
83. Searle A, Norman P, Thompson R, Vedhara K. Illness representations among patients with type 2 diabetes and their partners: relationships with self-management behaviors. J Psychosom Res 2007; 63: 175-84.
84. Searle A, Norman P, Thompson R, Vedhara K. A prospective examination of illness beliefs and coping in patients with type 2 diabetes. Br J Health Psychol 2007; 12: 621-38.
85. Hislop AL, Fegan PG, Schlaeppi MJ, Duck M, Yeap BB. Prevalence and associations of psychological distress in young adults with type 1 diabetes. Diabet Med 2008; 25: 91-6.
86. Poleshuck EL, Bair MJ, Kroenke K, Damush TM, Tu W, Wu J, et al. Psychosocial stress and anxiety in musculoskeletal pain patients with and without depression. Gen Hosp Psychiatry 2009; 31: 116-22.
87. Adriaanse MC, Pouwer F, Dekker JM, Nijpels G, Stehouwer CD, Heine RJ, et al. Diabetes-related symptom distress in association with glucose metabolism and comorbidity: the Hoorn Study. Diabetes Care 2008; 31: 2268-70.